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Methicillin-resistant Staphylococcus aureus (MRSA) con-
tinues to be one of most important causes of health care-
associated infections. Its ubiquity and increasing vanco-
mycin nonsusceptibility have contributed to the complexity
of treatment of infections caused by this pathogen.
Guidelines on the therapeutic monitoring of vancomycin
and treatment of MRSA infections were recently issued by
the Infectious Disease Society of America. In the advent of
the issuance of these guidelines, a symposium on the
“Treatment of MRSA Infections in Taiwan” was held in early1684-1182/$36 Copyright ª 2013, Taiwan Society of Microbiology. Publ
http://dx.doi.org/10.1016/j.jmii.2013.04.0102012 to address the management of these infections in the
local settings. Experts on infectious diseases in Taiwan
convened and issued a guideline for the treatment of MRSA
infections involving the skin and soft tissue, musculoskel-
etal, respiratory, cardiovascular, and central nervous
systems.
Other important issues addressed in the symposium were
the reporting of minimum inhibitory concentrations (MICs),
the dosage, and therapeutic drug monitoring of vancomycin.
Determination of vancomycin MIC was recommended in pa-
tientswithcomplicatedMRSA infections or treatment failure.
Vancomycin dosages of 30e60 mg/kg of actual body weight
perdaygivenat an interval of 6e12hourswere recommended
for patients with normal renal function. For seriously ill pa-
tients, including patients with bacteremia, sepsis, meningi-
tis, osteomyelitis, pneumonia, and severe skin and soft tissue
infections, a loading dose of 25e30 mg/kg (based on actual
body weight) may be considered. Serum trough levels should
be obtained just before the fourth or fifth dose and vanco-
mycin dosage should be adjusted to attain trough serum
vancomycin concentrations of 15e20 mg/mL when the van-
comycin MIC is 1 mg/mL (Table 1).
The guidelines were established based on the local
epidemiology, susceptibility patterns of MRSA, and expert
consensus. The guidelines were approved by the board
members of the Infectious Disease Society of Taiwan (IDST).
Free access to these guidelines is provided in the Journal of
Immunology, Microbiology and Infection (www.ejmii.com
and www.e-jmii.com) and the web site of IDST (http://
www.idsroc.org.tw/) to increase the access for medical
practitioners in Taiwan.ished by Elsevier Taiwan LLC. All rights reserved.
Table 1 Recommendations for the treatment of methicillin-resistant Staphylococcus aureus infections in Taiwan
Diagnosis Adults Pediatric dosage Duration Comments
Antibiotic of choice Alternatives
Skin and soft-tissue infection (SSTI)
Simple abscess or boils Incision and drainage d d d d





based on TMP) PO q12h
5e10 d Clindamycin could be used
when susceptibility results
are available.
Rifampin could be added
to any of the suggested
treatment regimens.
Doxycycline 100 mg PO q12h d Doxycycline: 45 kg, 2 mg
kg/dose PO q12h; >45 kg,
adult dose1
5e10 d
Minocycline 200 mg st, then 100 mg
PO q12h
d Minocycline 4 mg/kg PO 
1, then 2 mg/kg/dose PO q
5e10 d
Fusidic acid 500 mg PO q8e12h or
750 mg q12h
d Fusidic acid PO2 5e10 d
d d Linezolid 10 mg/kg/dose P




Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa
Linezolid 600 mg IV/
PO q12h
Vancomycin 15 mg/kg/dos 6h 7e14 d d
Teicoplanin 6e12 mg/kg/dose IV
q12h  three doses, then QD
Daptomycin 4 mg/kg/
dose IV QD
Teicoplanin 10 mg/kg IV q1
three doses, then 6e10 mg D
7e14 d d
d Tigecycline 100 mg st,
then 50 mg IV q12h
Linezolid 10 mg/kg/dose P 8h,





Vancomycin 30e60 mg/kg/day IV
in two to four divided dosesa
Daptomycin 6 mg/kg/
dose IV QD
Vancomycin 15 mg/kg/dos 6h 2 wk Addition of gentamicin or
rifampin to vancomycin is
not recommended.Teicoplanin 6e12 mg/kg/dose
IV q12h  three doses, then QD
d Teicoplanin 10 mg/kg IV q1 three





IV in two to four divided dosesa
Daptomycin 6e10 mg/
kg/dose IV QD
Vancomycin 15 mg/kg/dos 6h 4e6 wk Defined as bacteremia not
meeting the criteria of
uncomplicated bacteremia.
Addition of gentamicin or
rifampin to vancomycin is
not recommended.
Transition from parenteral
to oral agents should be
done cautiously and is not
recommended in those with
complicated bacteremia.
Teicoplanin 6e12 mg/kg/dose
IV q12h  three to six doses,
then 6e12 mg/kg/dose QD
d Teicoplanin 10 mg/kg IV q1 three
doses, then 6e10 mg/kg Q
4e6 wk
d d Daptomycin 6e10 mg/kg/d QD d




IV in two to four divided dosesa
d Vancomycin 15 mg/kg/dos 6h 4e6 wk Addition of gentamicin or
























not recommended.Teicoplanin 6e12 mg/kg/dose
IV q12h  three to six doses, then
6e12 mg/kg/dose QD
d Teicoplanin 10 mg/kg IV q  three




d Daptomycin 6e10 mg/kg/ IV QD 4e6 wk
Prosthetic valve
endocarditis
Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa þ Rifampin
300 mg PO q8h  Gentamicin 1 mg/
kg/dose q8h
d Vancomycin 15 mg/kg/do q6h4 þ
Gentamicin 1 mg/kg/dose 8h þ





Pneumonia Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa
d Vancomycin 15 mg/kg/do q6h 7e21 d d
Linezolid 600 mg PO/IV q12h d Teicoplanin 10 mg/kg IV q  three
doses, then 6e10 mg/kg Q
7e21 d d
Teicoplanin 6e12 mg/kg/dose
IV q12h  three doses, then
6e12 mg/kg/dose QD
d Linezolid 10 mg/kg/dose P V q8h,




d d d d d
Meningitis Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa  Rifampin




Vancomycin 15 mg/kg/do q6h 14 d d
Linezolid 600 mg IV/PO q12h d Linezolid 10 mg/kg/dose P V q8h,





Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa  Rifampin




600 mg PO QD or
300e450 mg PO q12hc
Vancomycin 15 mg/kg/do q6h 4e6 wk d
Linezolid 600 mg IV/PO q12h d Linezolid 10 mg/kg/dose P V q8h,
not to exceed 600 mg/dos
4e6 wk d
Osteomyelitis Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa
Linezolid 600 mg
PO/IV q12h
Vancomycin 15 mg/kg/do q6h5 >6 wk d
Daptomycin 6 mg/kg/dose IV QD d Teicoplanin 10 mg/kg IV q 
three doses, then 6e10 m QD
>6 wk d
TMPeSMX, TMP 4 mg/kg/dose PO/
IVq8e12h þ Rifampin 600 mg PO QDc
d Linezolid 10 mg/kg/dose P V q8h,
not to exceed 600 mg/dos
>6 wk d
Teicoplanin 6e12 mg/kg/dose IV
q12h  three doses, then QD
d Daptomycin 6e10 mg/kg/ IV QD >6 wk d
Fusidic acid 500 mg PO q8h or
750 mg q12h þ Rifampin 600 mg
PO QD or 300e450 mg PO q12hc
d d >6 wk d


































Diagnosis Adults Duration Comments
Antibiotic of choice Alternatives
Septic arthritis Vancomycin 30e60 mg/kg/day IV in
two to four divided dosesa
Linezolid 600 mg
PO/IV q12h
h5 3e4 wk d
Daptomycin 6 mg/kg/dose IV QD d
TMPeSMX, TMP 4 mg/kg/dose
PO/IVq8-12h þ Rifampin 600 mg PO QDc
d
Teicoplanin 6e12 mg/kg/dose
IV q12h  three doses, then QD
d
Fusidic acid 500 mg PO q8h or
750 mg q12h þ Rifampin 600 mg
QD or 300e450 mg PO q12hc
d
d Z days; IV Z intravenous; PO Z oral; q8h Z every 8 hours; q12h Z every 12 hours; QD Z
wk, weeks.
Pediatric notes
1. Doxycycline is not recommended for children younger than 8 years of age.
2. Fusidic acid dosage: <1 year of age, 50 mg/kg/day PO q8h; 1e5 years of age, 250 mg PO
3. Linezolid dosage is 600 mg PO q12h for children 12 years of age and 10 mg/kg/dose PO
4. The routine use of gentamicin or rifampin in children with bacteremia or infective endoc
5. The duration of treatment for osteoarticular infections should be individualized and a cours
for children.
a Vancomycin dosage is recommended to be given every 6 hours in immunocompromised pat
b Uncomplicated bacteremia is defined as catheter removal in catheter-related infection, fo
imens obtained 2e4 days after the initial set that do not grow methicillin-resistant Staphyloco
of effective therapy, no evidence of metastatic infection, exclusion of endocarditis, no evi
phlebitis, no prostheses in the joints or intravascular space
c Experts’ consensus.
150Pediatric dosage












































Teicoplanin 10 mg/kg IV q12h 
three doses, then 6e10 mg/kg QD
3e4 wk d
Linezolid 10 mg/kg/dose PO/IV q8h,
not to exceed 600 mg/dose3
3e4 wk d
Daptomycin 6e10 mg/kg/dose IV QD 3e4 wk d
d 3e4 wk d
every day; st Z stat; TMP Z trimethoprim; TMPeSMX Z trimethoprim-sulfamethoxazole;
q8h; 6e12 years of age, 500 mg PO q8h.
q8h for children <12 years of age.
arditis is not recommended and should be individualized.
e of 3e4 weeks and 4e6 weeks, respectively, for arthritis and osteomyelitis is recommended
ients
llow-up blood cultures performed on spec-
ccus aureus, defervescence within 72 hours
dence of central catheter-related thrombo-
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